Medication 7: Istradefylline: A Novel Approach to Motor Fluctuations
Istradefylline (Nourianz) is a newer medication approved for the treatment of Parkinson’s disease. It belongs to a class of drugs known as adenosine A2A receptor antagonists. Istradefylline works by blocking the action of adenosine A2A receptors in the brain, which are thought to play a role in motor function and the regulation of dopamine release.
Istradefylline is specifically indicated for the treatment of motor fluctuations in patients taking levodopa and carbidopa. By targeting a different neurotransmitter system, it provides an alternative approach to managing Parkinson’s symptoms, particularly when other medications may not be fully effective or cause side effects.
The most common side effects of istradefylline include dizziness, constipation, and insomnia. As with other Parkinson’s medications, healthcare providers will closely monitor patients taking istradefylline and adjust dosages to optimize symptom relief while minimizing side effects. (7)
